<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81584">
  <stage>Registered</stage>
  <submitdate>5/09/2006</submitdate>
  <approvaldate>21/09/2006</approvaldate>
  <actrnumber>ACTRN12606000414516</actrnumber>
  <trial_identification>
    <studytitle>Airway disease in older people</studytitle>
    <scientifictitle>Does ventilation heterogeneity predict airway hyperresponsiveness in asthmatic and COPD patients aged over 50 years?</scientifictitle>
    <utrn />
    <trialacronym>06AsCOPD</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma in older people</healthcondition>
    <healthcondition>Chronic Obstructive Pulmonary Disease (COPD) in older people</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ventilation heterogeneity and airway hyperresponsiveness are both observed on the same day in the one study visit (duration 2 hours) in asthmatic and COPD patients.</interventions>
    <comparator>No comparator.</comparator>
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Conducting airway ventilation heterogeneity are assessed on each patient</outcome>
      <timepoint>Ventilation heterogeneity is measured at the start of the visit</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose response ratio to methacholine challenge test assessed on each patient</outcome>
      <timepoint>The methacholine challenge test is conducted immediately after the ventilation heterogeneity is measured</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>NIL</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For asthmatic subjects: Inclusion criteria are doctor diagnosis of asthma, and FEV1 ³ 50% predicted. 
For COPD subjects: Inclusion criteria are doctor diagnosis of COPD, 15 pack year smoking history, FEV1 ³ 50% predicted.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Asthmatic exclusion criteria: are current smoking, or &gt; 10 pack year history of smoking, respiratory infection or prednisone use in the last 4 weeks.
COPD exclusion criteria are current smoking and respiratory infection in the last 4 weeks.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/04/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Asthma Foundation of New South Wales</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NIL</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Airway hyperresponsiveness (AHR) is an important feature of asthma, but its cause is unknown.  Recently, we discovered that uneven distribution of air within the lungs is a strong predictor of AHR. We hypothesise that structural changes in the airways cause this uneven distribution and make the airways prone to AHR.  Older people with asthma, particularly those with permanently narrowed airways, have more structural changes in their airways, whereas people with chronic obstructive pulmonary disease (COPD) have a different pattern of structural changes from that in asthma.  Evidence that there is a consistent relationship between AHR and uneven ventilation in these populations would support our hypothesis</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Woolcock Institute of Medical Research, Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Level 3 Building 92Royal Prince Alfred Hospital. Camperdown. NSW. 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec>X06-0046 </hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Department of Respiratory Medicine-Royal North Shore Hospital</ethicname>
      <ethicaddress>Level 8, Royal North Shore HospitalSt Leonards. NSW.  2065 </ethicaddress>
      <ethicapprovaldate />
      <hrec>0512-232M (SP)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ms Sue Downie</name>
      <address>PO Box M77
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 2 95157524</phone>
      <fax>+61 2 95506115</fax>
      <email>sued@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Newton-John</name>
      <address>PO Box M77
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>sarahnj@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>